Page 316 - Read Online

Ayoub et al. Nucleos(t)ide therapy for hepatitis B impacts HCC incidence

19. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki Reduction of chronic hepatitis B-related hepatocellular carcinoma
H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, with anti-viral therapy, including low risk patients. Aliment Pharmacol
Kumada H. Long-term entecavir treatment reduces hepatocellular Ther 2016;44:846-55.
carcinoma incidence in patients with hepatitis B virus infection. 32. Koklu S, Tuna Y, Gulsen MT, Demir M, Koksal AS, Kockar MC,
Hepatology 2013;58:98-107. Aygun C, Coban S, Ozdil K, Ataseven H, Akin E, Purnak T, Yuksel I,
20. Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Ataseven H, Ibis M, Yildirim B, Nadir I, Kucukazman M, Akbal E,
Leung JM, Lai JW, Lo AO, Chan HY, Wong VW. Entecavir treatment Yuksel O, Basar O, Alkan E, Baykal O. Long-term efficacy and safety
reduces hepatic events and deaths in chronic hepatitis B patients with of lamivudine, entecavir, and tenofovir for treatment of hepatitis B
liver cirrhosis. Hepatology 2013;58:1537-47. virus-related cirrhosis. Clin Gastroenterol Hepatol 2013;11:88-94.
21. Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, Wang 33. Idilman R, Gunsar F, Koruk M, Keskin O, Meral CE, Gulsen M,
CC, Su WW, Chen MY, Peng CY, Chien RN, Huang YW, Wang Elhan AH, Akarca US, Yurdaydin C. Long-term entecavir or tenofovir
HY, Lin CL, Yang SS, Chen TM, Mo LR, Hsu SJ, Tseng KC, Hsieh disoproxil fumarate therapy in treatment-naive chronic hepatitis B
TY, Suk FM, Hu CT, Bair MJ, Liang CC, Lei YC, Tseng TC, Chen patients in the real-world setting. J Viral Hepat 2015;22:504-10.
CL, Kao JH; C-TEAM study group and the Taiwan Liver Diseases 34. Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J,
Consortium. Four-year entecavir therapy reduces hepatocellular Arends P, Sypsa V, Manolakopoulos S, Mangia G, Gatselis N, Keskin
carcinoma, cirrhotic events and mortality in chronic hepatitis B O, Savvidou S, Hansen BE, Papaioannou C, Galanis K, Idilman R,
patients. Liver Int 2016;36:1755-64. Colombo M, Esteban R, Janssen HL, Lampertico P. Incidence and
22. Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, predictors of hepatocellular carcinoma in Caucasian chronic hepatitis
Kanamori A, Niinomi T, Yasuda S, Andou Y, Yamamoto K, Tanaka B patients receiving entecavir or tenofovir. J Hepatol 2015;62:363-70.
J. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis 35. Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico
in chronic hepatitis B patients: a propensity score analysis. J Hepatol P. Risk of hepatocellular carcinoma in chronic hepatitis B:
2013;58:427-33. assessment and modification with current antiviral therapy. J Hepatol
23. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, 2015;62:956-67.
Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje 36. Papatheodoridis GV, Manolakopoulos S, Touloumi G, Nikolopoulou
U, Beebe S, Kreter B. Long-term entecavir therapy results in the G, Raptopoulou-Gigi M, Gogos C, Vafiadis-Zouboulis I, Karamanolis
reversal of fibrosis/cirrhosis and continued histological improvement D, Chouta A, Ilias A, Drakoulis C, Mimidis K, Ketikoglou I, Manesis
in patients with chronic hepatitis B. Hepatology 2010;52:886-93. E, Mela M, Hatzis G, Dalekos GN, Grp HGS. Hepatocellular
24. Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, Wu C, Wu JC. carcinoma risk in HBeAg-negative chronic hepatitis B patients with
Association of nucleos(t)ide analogue therapy with reduced risk or without cirrhosis treated with entecavir: HepNet.Greece cohort. J
of hepatocellular carcinoma in patients with chronic hepatitis B: a Viral Hepat 2015;22:120-7.
nationwide cohort study. Gastroenterology 2014;147:143-51.e5. 37. Wang JP, Kao FY, Wu CY, Hung YP, Chao Y, Chou YJ, Li
25. Coffin CS, Rezaeeaval M, Pang JX, Alcantara L, Klein P, Burak KW, CP. Nucleos(t)ide analogues associated with a reduced risk of
Myers RP. The incidence of hepatocellular carcinoma is reduced in hepatocellular carcinoma in hepatitis B patients: a population-based
patients with chronic hepatitis B on long-term nucleos(t)ide analogue cohort study. Cancer 2015;121:1446-55.
therapy. Aliment Pharmacol Ther 2014;40:1262-9. 38. Huang G, Lau WY, Wang ZG, Pan ZY, Yuan SX, Shen F, Zhou WP,
26. Gordon SC, Lamerato LE, Rupp LB, Li J, Holmberg SD, Moorman Wu MC. Antiviral therapy improves postoperative survival in patients
AC, Spradling PR, Teshale EH, Vijayadeva V, Boscarino JA, Henkle with hepatocellular carcinoma: a randomized controlled trial. Ann
EM, Oja-Tebbe N, Lu M; CHeCS Investigators. Antiviral therapy for Surg 2015;261:56-66.
chronic hepatitis B virus infection and development of hepatocellular 39. Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, Guo W, Zhang H, Wang
carcinoma in a US population. Clin Gastroenterol Hepatol H, Cheng S, Cao G. Effect of antiviral treatment with nucleotide/
2014;12:885-93. nucleoside analogs on postoperative prognosis of hepatitis B virus-
27. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, related hepatocellular carcinoma: a two-stage longitudinal clinical
Washington MK, Germanidis G, Flaherty JF, Schall RA, Bornstein study. J Clin Oncol 2013;31:3647-55.
JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. 40. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT.
Regression of cirrhosis during treatment with tenofovir disoproxil Association between nucleoside analogues and risk of hepatitis B
fumarate for chronic hepatitis B: a 5-year open-label follow-up study. virus-related hepatocellular carcinoma recurrence following liver
Lancet 2013;381:468-75. resection. JAMA 2012;308:1906-14.
28. Kim W, Berg T, Loomba R, Aguilar Schall R, Dinh P, Yee L, Martins E, 41. Zhou Y, Zhang Z, Zhao Y, Wu L, Li B. Antiviral therapy decreases
Flaherty J, Gurel S, Buti M. Long term tenofovir disoproxil fumarate recurrence of hepatitis B virus-related hepatocellular carcinoma after
(TDF) therapy and the risk of hepatocellular carcinoma. J Hepatol curative resection: a meta-analysis. World J Surg 2014;38:2395-402.
2013;58:S19. 42. Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, Lui YY,
29. Wang HM, Hung CH, Lee CM, Lu SN, Wang JH, Yen YH, Kee Chan AT, Sung JJ, Yeo W, Chan HL, Mok TS. Clinical scoring system
KM, Chang KC, Tseng PL, Hu TH, Chen CH. Three-year efficacy to predict hepatocellular carcinoma in chronic hepatitis B carriers. J
and safety of tenofovir in nucleos(t)ide analog-naive and nucleos(t) Clin Oncol 2010;28:1660-5.
ide analog-experienced chronic hepatitis B patients. J Gastroenterol 43. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, But DY,
Hepatol 2016;31:1307-14. Chan AO, Wong BC, Mizokami M, Lai CL. Independent risk factors
30. Sinn DH, Lee J, Goo J, Kim K, Gwak GY, Paik YH, Choi MS, Lee and predictive score for the development of hepatocellular carcinoma
JH, Koh KC, Yoo BC, Paik SW. Hepatocellular carcinoma risk in in chronic hepatitis B. J Hepatol 2009;50:80-8.
chronic hepatitis B virus-infected compensated cirrhosis patients with 44. Abu-Amara M, Cerocchi O, Malhi G, Sharma S, Yim C, Shah H,
low viral load. Hepatology 2015;62:694-701. Wong DK, Janssen HL, Feld JJ. The applicability of hepatocellular
31. Lin D, Yang HI, Nguyen N, Hoang J, Kim Y, Vu V, Le A, Chaung K, carcinoma risk prediction scores in a North American patient
Nguyen V, Trinh H, Li J, Zhang J, Hsing A, Chen CJ, Nguyen MH. population with chronic hepatitis B infection. Gut 2016;65:1347-58.

308 Hepatoma Research ¦ Volume 3 ¦ December 20, 2017